Relationship between Oxidative Stress Biomarkers and Visual Field Progression in Patients with Primary Angle Closure Glaucoma

Table 2

Baseline demographic and disease characteristics of PACG subjects with and without visual field progression.

Variable	No progression ()	Progression ()	t value	value
Age (year)			2.134	0.036^&
Gender (male/female)	21/30	16/27	0.154	0.695
BMI (m^2/kg)			1.112	0.269^&
SBP (mm Hg)			0.349	0.728^&
DBP (mm Hg)			0.409	0.684^&
Smoking (yes/no)	10/41	13/30	1.425	0.233
Drinking (yes/no)	15/36	9/34	0.883	0.347
Number of topical glaucoma medications,
0	2	2
1-2	20	13
>2	35	22	0.382	0.938
Visual acuity (logMAR)			1.063	0.290^&
IOP (mm Hg)			0.667	0.506^&
VCDR			0.277	0.783^&
CCT (mm)			0.391	0.697^&
ACD (cm)			2.387	0.019^&
AL (cm)			1.455	0.149^&
MS(dB)			1.185	0.239^&
MD (baseline, dB)			1.125	0.264^&
MD (6 months, dB)			1.395	0.166^&
MD (12 months, dB)			1.386	0.169^&
MD (18 months, dB)			1.685	0.095^&
MD (24 months, dB)			1.835	0.070^&
GPX (U/L)			0.541	0.590^&
GR (U/L)			0.503	0.616^&
SOD (U/mL)			3.333	0.001^&
TAS			4.557	<0.001^&
MDA (umol/l)			2.779	0.007^&
H2O2 (umol/l)			1.094	0.277^&

^&Independent-samples -test; ^#Mann-Whitney test; test. BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; IOP: intraocular pressure; VCDR: vertical cup-disc ratio; CCT: central corneal thickness; ACD: anterior chamber depth; AL: axial length; MD: visual field mean deviation; MS: visual field mean sensitivity; SOD: superoxide dismutase; TAS: total antioxidant status; H₂O₂: hydrogen peroxide; MDA: malondialdehyde; GPX: glutathione peroxidase; GR: glutathione reductase.